Clinical trials: Fuchs Dystrophy
Fuchs' Endothelial Dystrophy, Cataract
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry…
- Trial name
- NCT04057053
- Testing
- Netarsudil 0.02% Ophthalmic Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Keratoconus, Fuchs Dystrophy
Femtolaser Assisted Keratoplasty Versus Conventional Keratoplasty
This pilot study will compare upto 15 patients undergoing femtolaser assisted keratoplasty (using CE[Conformité Européene] approved femtolaser apparatus) with upto 15 patients undergoing conventional keratoplasty with a manual…
- Conditions
- Keratoconus, Fuchs Dystrophy, Corneal Disease
- Trial name
- NCT03619434
- Testing
- Femtosecond Laser, Trephine blade
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Southampton
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty
The purpose of this study is to report the early clinical outcomes in patients undergoing Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) for corneal edema secondary to corneal endothelial cell dysfunction, and to…
- Trial name
- DSAEK (NCT00744796)
- Testing
- DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Fuchs' Endothelial Dystrophy
Eye Drops for Early Morning-Associated Corneal Swelling of the Cornea
This study evaluates the efficacy of hyperosmolar eye drops on early morning edema of the cornea in patients with Fuchs' endothelial corneal dystrophy (FECD).
- Trial name
- EDEMAS (NCT04140422)
- Testing
- Hyperosmolar eye drops
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- University Eye Hospital, Freiburg
Endothelial Corneal Dystrophy
Predictive Factors of Good Results After Primary Descemet's Membrane Endothelial Keratoplasty (DMEK)
Aim: Identify predictive factors of good results after primary Descemet's Membrane Endothelial Keratoplasty (DMEK) in Fuchs Endothelial Corneal Dystrophy (FECD).
- Trial name
- GOODRMEK (NCT04469933)
- Volunteers
- 102 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy
The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK
This study aims to investigate the influence of postoperative head position on clinical outcomes after DMEK via a wearable sensor.
- Conditions
- Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Chemical Burn of Cornea, Posterior Polymorphous Corneal Dystrophy
- Trial name
- NCT04387331
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Peter Wiedemann
Corneal Disease, Fuch's Dystrophy
Cornea Donor Study
The Cornea Donor Study (CDS) was designed as a prospective cohort study with the following objectives: To determine whether the graft-failure rate over a 5-year follow-up period following corneal transplantation is the same when…
- Conditions
- Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
- Trial name
- CDS (NCT00006411)
- Testing
- corneas assigned by donor age group
- Where
- United States
- Volunteers
- 1,090 people
- Sponsor
- National Eye Institute (NEI)
Fuchs' Endothelial Dystrophy, Cataract
Risk Assessment for Progression to DMEK Following Cataract Surgery in Fuchs Endothelial Corneal Dystrophy
Justification. Fuchs' corneal endothelial dystrophy (FECD) is one of the main causes of corneal transplantation. In many cases, the corneal decompensation derived from this dystrophy is triggered as a consequence of cataract…
- Trial name
- NCT04072029
- Testing
- Phacoemulsification with intraocular lens implantation
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Corneal Edema, Fuchs Dystrophy
Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
Single center, phase 1 study to evaluate the safety and tolerability of EO1404 in subjects with corneal edema secondary to pseudophakic bullous keratopathy or Fuch's endothelial dystrophy.
- Conditions
- Corneal Edema, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Pseudophakic Bullous Keratopathy
- Trial name
- NCT04191629
- Testing
- EO1404, Endothelial brushing or Descemet stripping
- Where
- Mexico
- Volunteers
- 35 people
- Sponsor
- Valeria Sanchez-Huerta
Keratoconus, Fuchs' Endothelial Dystrophy
Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study
Immune rejection episodes after penetrating keratoplasty occur in 30% of patients and constitute one of the main factors reducing graft survival. They mainly occur during the first 18 months.
- Conditions
- Keratoconus, Fuchs' Endothelial Dystrophy, Congenital Hereditary Stromal Dystrophy of the Cornea
- Trial name
- IDEXACOR (NCT02834260)
- Testing
- Dexamethasone implant OZURDEX
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Fuchs' Endothelial Dystrophy
Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.
With the increasing popularity of endothelial keratoplasty, a coincident increase in the rate of fungal infections post-keratoplasty has been seen in the United States.
- Trial name
- NCT04018417
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Cornea Research Foundation of America
Fuchs' Endothelial Dystrophy
DMEK Versus DSAEK Study
The purpose of this study is to determine whether corneal transplantation by Descemet Membrane Endothelial Keratoplasty more favourable and cost-effective is compared to Descemet Stripping Automated Endothelial Keratoplasty for…
- Trial name
- DMEK (NCT02793310)
- Testing
- DMEK, DSAEK
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- Maastricht University Medical Center
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)
This blinded, randomized study compares the use of air and sulfur hexaflouride (SF6) tamponade in Descemet Membrane Endothelial Keratoplasty.
- Trial name
- NCT03407755
- Testing
- Intraocular gas
- Where
- Denmark
- Volunteers
- 104 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy
Study of Endothelial Keratoplasty Outcomes
Endothelial keratoplasty is a cornea-sparing transplant technique that replaces only the diseased endothelial cell layer of the patient's cornea.
- Conditions
- Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy, Iridocorneal Endothelial Syndrome, Posterior Polymorphous Dystrophy
- Trial name
- NCT00800111
- Testing
- endothelial keratoplasty
- Where
- United States
- Volunteers
- 2,593 people
- Sponsor
- Cornea Research Foundation of America
Fuchs' Endothelial Dystrophy, Fuchs Dystrophy
Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy
The cornea forms our "window to the world". Hence, its transparency is of utmost importance for vision. Corneal endothelium plays a central role in the maintenance of a transparent corneal stroma.
- Conditions
- Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Corneal Endothelial Dystrophy, Corneal Endothelial Cell Loss
- Trial name
- NCT03575130
- Testing
- Ripasudil eye drops, Optive eye drops, Descemetorhexis
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Fuchs' Endothelial Dystrophy
The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
The purpose of this study is to gain further insights into the molecular pathogenesis of Fuchs' endothelial corneal dystrophy (FECD), to identify targets for potential specific drug therapy.
- Trial name
- NCT01795001
- Testing
- No intervention
- Where
- Belgium
- Volunteers
- 460 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Fuchs' Endothelial Dystrophy
OCT-guided DSAEK Graft Shaping and Smoothing
The primary goal of this study is to determine if excimer laser smoothing of the cornea before Descemet's stripping automated endothelial keratoplasty (DSAEK)improves postoperative Best Spectacle Corrected Visual Acuity (BSCVA).
- Trial name
- DSAEK (NCT01586234)
- Testing
- DSAEK with graft shaping and smoothing, Standard DSAEK
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Oregon Health and Science University
Keratoconus, Fuchs' Endothelial Dystrophy
Long Term Cornea Graft Survival Study
Corneal transplantation have been performed for several decades, follow-up time in some centers now exceeds 30 years. Published long term (10 years and up) graft survivals vary considerably from center to center.
- Trial name
- BELIEvE (NCT02849808)
- Where
- France
- Volunteers
- 564 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Fuchs' Endothelial Dystrophy
Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy
Fuchs Endothelial Dystrophy (FED) is a degenerative disease affecting the corneal endothelium. The current gold-standard for treatment of severe FED is endothelial keratoplasty, wherein a cadaveric Descemet's membrane /…
- Trial name
- NCT03275896
- Testing
- Descemet Membrane Transplantation
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Singapore National Eye Centre
Fuchs' Endothelial Dystrophy, Cataract
Using the Optovue OCT to Select IOL Power
Many patients with endothelial dysfunction also present with cataracts. It is therefore common practice to perform cataract extraction and intraocular lens (IOL) implantation during the same operation and immediately prior to…
- Trial name
- NCT01361282
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Legacy Health System